The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer

Overview

Journal Technol Cancer Res Treat

Specialties Biomedical Engineering
Oncology
Pharmacology

Date 2024 Jul 23

PMID 39043046

Authors

Li Li

Yihan Xu

Yuchao Wang

Qian Zhang

Yan Wang

Chunhua Xu

Affiliations

Soon will be listed here.

Abstract

Finding biomarkers related to non-small cell lung cancer (NSCLC) is helpful for the diagnosis and precise treatment of lung cancer. The relationship between serum tumor M2-pyruvate kinase (TuM2-PK), carcinoembryonic antigen (CEA), and cytokeratin 19 fragment (CYFRA21-1) and NSCLC was analyzed. The serum levels of TuM2-PK, CEA, and CYFRA21-1 in 184 patients with the NSCLC group, 60 patients with the benign lung disease (BLD) group, and 90 healthy controls (HC) group were detected. The levels of TuM2-PK were measured by using an enzyme-linked immunosorbent assay. The detection methods of CEA and CYFRA21-1 were electrochemiluminescence. The receiver operating characteristic (ROC) curve was drawn to evaluate the diagnostic value of TuM2-PK, CEA, and CYFRA21-1 on NSCLC. The Kaplan-Meier survival curve was drawn to evaluate the survival status in NSCLC patients with different serum levels of TuM2-PK, CEA, and CYFRA21-1. Serum levels of TuM2-PK, CEA, and CYFRA21-1 in the NSCLC group were significantly higher than those in the BLD group and the HC group ( < .01). Serum levels of TuM2-PK, CEA, and CYFRA21-1 in NSCLC patients were associated with the tumor lymph node metastasis stage ( < .05), lymph node metastasis ( < .05), and distant metastasis ( < .05). The ROC curve showed that the area under the curve of serum levels of TuM2-PK, CEA, and CYFRA21-1 was 0.814, 0.638, and 0.719, respectively, and that the combination of the above 3 was 0.918. The Kaplan-Meier survival curve showed that the 1-, 3- and 5-year survival rate in NSCLC patients with positive TuM2-PK, CEA, and CYFRA21-1 was significantly lower than that in NSCLC patients with negative TuM2-PK, CEA, and CYFRA21-1, respectively ( < .05). Serum TuM2-PK, CEA, and CYFRA21-1 levels have high clinical values in the diagnosis of NSCLC, and can effectively judge the prognosis of patients.

References

Liu J, Zhu H, Jiang H, Zhang H, Wu D, Hu X . Tumor M2 pyruvate kinase in diagnosis of nonsmall cell lung cancer: A meta-analysis based on Chinese population. J Cancer Res Ther. 2015; 11 Suppl 1:C104-6. DOI: 10.4103/0973-1482.163857. View

Bandara I, Baltatzis M, Sanyal S, Siriwardena A . Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer. World J Surg Oncol. 2018; 16(1):56. PMC: 5853155. DOI: 10.1186/s12957-018-1360-3. View

Sriram K, Larsen J, Yang I, Bowman R, Fong K . Genomic medicine in non-small cell lung cancer: paving the path to personalized care. Respirology. 2010; 16(2):257-63. DOI: 10.1111/j.1440-1843.2010.01892.x. View

Luftner D, Mazurek S, Henschke P, Mesterharm J, Schildhauer S, Geppert R . Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer. Anticancer Res. 2003; 23(2A):991-7. View

Li J, Chen Y, Wang X, Wang C, Xiao M . The value of combined detection of CEA, CYFRA21-1, SCC-Ag, and pro-GRP in the differential diagnosis of lung cancer. Transl Cancer Res. 2022; 10(4):1900-1906. PMC: 8797414. DOI: 10.21037/tcr-21-527. View

Dal Bello M, Filiberti R, Alama A, Orengo A, Mussap M, Coco S . The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. J Transl Med. 2019; 17(1):74. PMC: 6408784. DOI: 10.1186/s12967-019-1828-0. View

Demir A, Erdenen F, Muderrisoglu C, Toros A, Bektas H, Gelisgen R . Diagnostic and prognostic value of tumor M2-pyruvate kinase levels in patients with colorectal canhcer. Turk J Gastroenterol. 2013; 24(1):36-42. View

Brown D, Zingone A, Yu Y, Zhu B, Candia J, Cao L . Relationship between Circulating Inflammation Proteins and Lung Cancer Diagnosis in the National Lung Screening Trial. Cancer Epidemiol Biomarkers Prev. 2018; 28(1):110-118. PMC: 6325020. DOI: 10.1158/1055-9965.EPI-18-0598. View

Fu Y, Li D, Zhu Y, Yan S, Wang X, Lian Z . Application Value of CYFRA21-1 Combined with NSE, CEA, and SCC-Ag in Lung Cancer. Clin Lab. 2024; 70(4). DOI: 10.7754/Clin.Lab.2023.230662. View

10.

Liu C, Li H, Jia J, Ruan X, Liu Y, Zhang X . High Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Expression Promotes Proliferation, Migration, and Invasion of Non-Small Cell Lung Cancer via ERK/Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway. Med Sci Monit. 2019; 25:5143-5149. PMC: 6640658. DOI: 10.12659/MSM.913308. View

11.

Grunnet M, Sorensen J . Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2011; 76(2):138-43. DOI: 10.1016/j.lungcan.2011.11.012. View

12.

Esencay M, Watson A, Mukherjee K, Hanicq D, Gubernick S . Biomarker strategy in lung cancer. Nat Rev Drug Discov. 2017; 17(1):13-14. DOI: 10.1038/nrd.2017.166. View

13.

Xu C, Yuan Q, Hu H, Wang W, Zhang Q, Li L . Expression of Cripto-1 predicts poor prognosis in stage I non-small cell lung cancer. J Cell Mol Med. 2020; 24(17):9705-9711. PMC: 7520286. DOI: 10.1111/jcmm.15518. View

14.

Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R . The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452(7184):230-3. DOI: 10.1038/nature06734. View

15.

Moazzezy N, Bouzari S, Oloomi M . Comparative Study of Blood, Tissue and Serum Levels of Carcinoembryonic Antigen (CEA) Detection in Breast Cancer. Asian Pac J Cancer Prev. 2019; 20(10):2979-2985. PMC: 6982663. DOI: 10.31557/APJCP.2019.20.10.2979. View

16.

Korkmaz E, Koksal D, Aksu F, Dikmen Z, Icen D, Maden E . Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer. Clin Biochem. 2018; 58:15-19. DOI: 10.1016/j.clinbiochem.2018.05.001. View

17.

Kumar Y, Gurusamy K, Pamecha V, Davidson B . Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis. Pancreas. 2007; 35(2):114-9. DOI: 10.1097/mpa.0b013e3180537237. View

18.

Oremek G, Kukshaite R, Sapoutzis N, Ziolkowski P . [The significance of TU M2-PK tumor marker for lung cancer diagnostics]. Klin Med (Mosk). 2007; 85(7):56-8. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Akinci Ozyurek B, Sahin Ozdemirel T, Buyukyaylaci Ozden S, Erdogan Y, Kaplan B, Kaplan T . Prognostic Value of the Neutrophil to Lymphocyte Ratio (NLR) in Lung Cancer Cases. Asian Pac J Cancer Prev. 2017; 18(5):1417-1421. PMC: 5555556. DOI: 10.22034/APJCP.2017.18.5.1417. View